公司董事长为王海波。王海波先生:1960年10月出生,中国国籍,匈牙利永久居留权,硕士学历,副教授,于一九九六年十一月获委任为本公司执行董事，亦为董事会主席及总经理。同时亦兼任本公司之附属公司泰州复旦张江药业公司董事长及风屹（香港）控股有限公司董事。他于一九九六年十一月创立本公司。他于一九九五年五月至一九九六年六月为复旦大学副教授，曾发表多篇论文，因而获颁多项奖项，如国家星火三等奖、教委二等奖及上海市科技进步奖。他毕业于复旦大学，于一九八三年七月获颁生物学士学位，及于一九八六年七月获颁硕士学位。他亦曾担任浙江升华拜克生物股份有限公司（一间于上海证券交易所上市的公司，上交所股份代号： 600226）的技术总监。Fudan Zhangjiang released a report for the third quarter of 2021 that the company's operating income was 299 million yuan, up 14.77% from the same period last year. The net profit belonging to shareholders of listed companies was 53.1288 million yuan, down 4.73% from the same period last year; the net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 47.3208 million yuan, down 0.56% from the same period last year; and basic earnings per share was 0.05 yuan.
According to the third quarterly report of Fudan Zhangjiang 2021, the company's main income was 698 million yuan, up 40.69% from the same period last year; the net profit was 119 million yuan, up 39.8% from the same period last year; and the non-net profit was 102 million yuan, up 75.28% from the same period last year. Among them, in the third quarter of 2021, the company's main income in a single quarter was 299 million yuan, up 14.77% from the same period last year; the net profit in a single quarter was 53.1288 million yuan, down 4.73% from the same period last year The non-net profit in a single quarter was 47.3208 million yuan, down 0.56% from the same period last year; the debt ratio was 18.81%, the investment income was 10.1447 million yuan, the financial expenses were-3.8106 million yuan, and the gross profit margin was 92.97%.
The stock has no agency rating in the last 90 days. In the past three months, the net outflow of financing was 2.9977 million, and the financing balance decreased; the net outflow of securities was 2.9083 million, and the balance of securities lending decreased. According to the Securities Star valuation analysis tool, Fudan Zhangjiang (688505) good company has a rating of 3.5 stars, a good price rating of 1 star, and a comprehensive valuation rating of 2 stars.
The chairman of the company is Wang Haibo. Mr. Wang Haibo: born in October 1960, Chinese nationality, Hungarian permanent residence, master's degree, associate professor, was appointed as executive director, chairman and general manager of the board of directors in November 1996. At the same time, he is also the chairman of Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd., a subsidiary of the Company, and a director of Fengyi (Hong Kong) Holdings Limited. He founded the company in November 1996. He was an associate professor at Fudan University from May 1995 to June 1996. He has published a number of papers and has been awarded a number of awards, such as the third prize of the National Spark Award, the second prize of the Education Commission and the Shanghai Science and Technology Progress Award. He graduated from Fudan University and received a Bachelor's degree in Biology in July 1983 and a Master's degree in July 1986. He also served as the Technical Director of Zhejiang Shenghua Baike Biology Co., Ltd., a company listed on the Shanghai Stock Exchange (Shanghai Stock Exchange Stock Code: 600226).
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.
